Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.
LATEST RENAL CELL CARCINOMA CONTENT
Tivozanib Explored in Second-Line ccRCC
Adjuvant IO Exposure Complicates Treatment Selection for mRCC
Risk Status Provides Less Clear Picture in IO/TKI Era of RCC Treatment
NCCN Guidelines in nccRCC Weigh New Data for Combinations
Phase 2 Trials Support NCCN’s Inclusion of Combinations for nccRCC
Tailoring TKI Dosing Strategies to Real-World Patients With RCC
Clinical and Logistical Factors Determine Treatment Choice for nccRCC
Oncologists Discuss Choice of Frontline IO/TKI for Metastatic RCC
CASE-BASED ROUNDTABLES
Advertisement
Advertisement